|
|||||
|
|
Efficacy and safety of MYL-1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 study |
|
| Authors: | Thomas C. Blevins MD Abhijit Barve MD Bin Sun Yaron Raiter MD Patrick Aubonnet MD Rafael Muniz MD Sandeep Athalye MD Michael Ankersen PhD |
| Affiliation: | 1. Texas Diabetes and Endocrinology, Austin, Texas;2. Mylan Inc, Canonsburg, Pennsylvania;3. Mylan EPD, Amstelveen, The Netherlands;4. Mylan EPD, Allschwil, Switzerland;5. Biocon Research Ltd, Bangalore, India |
| Abstract: | |
| Keywords: | biosimilar efficacy insulin glargine safety type 2 diabetes |